Treatment with Combination of Mithramycin A and Tolfenamic Acid Promotes Degradation of Sp1 Protein and Synergistic Antitumor Activity in Pancreatic Cancer

Previous studies showed that both mithramycin (MIT) and tolfenamic acid (TA) inhibits the activity of the transcription factor Sp1. In the present study, we sought to determine whether treatment with a combination of these two compounds has a synergistic effect on Sp1 activity and pancreatic cancer...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jia, Zhiliang, Gao, Yong, Wang, Liwei, Li, Qiang, Zhang, Jun, Le, Xiangdong, Wei, Daoyan, Yao, James C., Chang, David Z., Huang, Suyun, Xie, Keping
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2840649/
https://ncbi.nlm.nih.gov/pubmed/20086170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3282
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky